PHARMACY

Pharmacy automation provider Kirby Lester goes live with new online store

BY Michael Johnsen

LAKE FOREST, Ill. — Pharmacy automation provider Kirby Lester on Thursday went live with its new online store

Kirby Lester maintains one of the largest markets of automatic tablet/capsule counter sales in the United States. 

According to the company, more Kirby Lester counters are used to dispense prescriptions in retail, mail-order, hospital and long-term care pharmacies and manufacturing facilities than all other automated dispensing systems combined; more than 40,000 pharmacies worldwide rely on Kirby Lester for their counting needs.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

APhA Foundation names William Ellis as recipient of 2014 Jacob W. Miller Award

BY Antoinette Alexander

WASHINGTON — The American Pharmacists Association Foundation announced on Thursday that William Ellis is the recipient of the 2014 APhA Foundation Jacob W. Miller Award.

He was selected in recognition of his leadership and outstanding service as the first full-time executive director of the APhA Foundation from 1997 until 2010, the APhA stated.

“It is a tremendous honor to receive an award that was established to recognize the many contributions that Jake Miller has made to the profession of pharmacy and to the APhA Foundation. I consider it a privilege to have had the opportunity to be part of the APhA Foundation’s cutting edge work to improve the quality of consumer health outcomes and to help advance new patient care roles for the profession,” Ellis said.

The Jacob W. Miller Award recognizes an individual who has advanced the mission of the APhA Foundation by demonstrating active involvement in Foundation programs, exemplary support in establishing and/or maintaining APhA Foundation initiatives or outstanding leadership in carrying out the mission of the APhA Foundation. It was established in 2000 to honor Jacob W. Miller, who served as president of the APhA Foundation from 1991 to 2000.

During his tenure, Ellis developed and directed research initiatives, projects and programs, including the Project ImPACT (Improving Persistence and Compliance with Therapy) series, which has provided strong evidence for the expanded role of the pharmacist in healthcare. He introduced HealthMapRx, a voluntary health benefit for self-insured employers, proven to reduce healthcare costs and improve health outcomes for employees and dependents with diabetes. Ellis also established the APhA Foundation’s Pinnacle Awards, which honor those who make significant contributions to the medication use process.

Ellis will be honored for his achievements during the APhA Annual Meeting and Expo to be held March 28 to 31 in Orlando. The official award presentation will take place on March 31 at the APhA Foundation Contributors’ Breakfast, where Ellis will personally receive the award from Miller. Miller was instrumental in hiring Ellis as executive director of the APhA Foundation.

Ellis is currently executive director for the Board of Pharmacy Specialties. Ellis also is chair of the Council on Credentialing in Pharmacy and chair of the Board of Visitors for the Philadelphia College of Pharmacy. Prior to his work with the APhA Foundation, he was EVP of the Pennsylvania Society of Health-System Pharmacists.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Teva’s Synribo gets FDA approval

BY Ryan Chavis

JERUSALEM — Teva Pharmaceutical Industries on Thursday announced that the Food and Drug Administration has granted full approval of Synribo (omacetaxine mepesuccinate) for injection.

The drug is indicated for adult patients with chronic phase or accelerated phase chronic myeloid leukemia with resistance and/or intolerance to two or more tyrosine kinase inhibitors.

“With this approval, based on the final analysis of two Phase-2 trials that evaluated efficacy and tolerability data of Synribo, we believe healthcare providers can be even more confident in the clinical profile of this important medicine,” said Rob Koremans, M.D., president and CEO, Global Specialty Medicines. “This approval reinforces our ongoing commitment to providing Synribo to people living with CML who have failed two or more TKI therapies.“

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES